BioSpace News Archive

Kidney patients need better, more relevant education to best participate in the decision-making about their treatment, a new study published in the National Kidney Foundation’s American Journal of Kidney Diseases shows.

Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, announced it will soon open a high speed multi-purpose fill finish line in its state-of-the-art commercial manufacturing facility located in San Diego, CA.

The integration of the sequence of each single cell coupled with IsoPlexis’ proprietary functional proteomics accelerates insights into discovery biology & development of advanced medicines

Seres Therapeutics, Inc., a leading microbiome therapeutics company, announced that management will present a corporate overview at two upcoming investor conferences

ARTMS Inc. is pleased to announce the production of Ga-68 Chloride using a medical cyclotron in a US based commercial nuclear pharmacy.

Establishment Labs Holdings Inc., a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, announced that CEO and Founder Juan José Chacón-Quirós and Chief Financial Officer Renee Gaeta will participate in the Jefferies Virtual Healthcare Conference, which is being held June 1-4, 2021.

UroGen Pharma Ltd., a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, announced that it will present at the following virtual conferences in June

Baxter International Inc., a global leader in acute care, announced the global launch of PrisMax 2, the latest version of the company’s next-generation platform.

Xencor, Inc. announced it has entered into a technology license agreement with Bristol-Myers Squibb Company under which Bristol Myers Squibb will have non-exclusive access to Xencor’s Xtend™ Fc technology to extend the half-life of a novel antibody combination therapy that is intended to neutralize the SARS-CoV-2 virus for treatment or prevention of COVID-19.

Modular Medical, Inc., a medical device company focused on next generation insulin delivery technologies to widen the accessibility of insulin pumps to a greater share of people with type 1 and type 2 diabetes, is pleased to announce the appointment of industry veteran Lynn O’Connor Vos to its board of directors.